Related Experiment Video
Updated: Jul 5, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Correlation of miR-155-5p, KRAS, and CREB Expression in Patients with Acute Myeloid Leukemia
Background:
Acute myeloid leukemia (AML) is a type of blood cancer involving numerous aberrant genes and microRNAs. MiRNAs are non-coding sequences that have been proven to be players in the biological processes of various cancers. The present study is designed to illustrate the relationship between miR-155, KRAS, and CREB.
Methods:
This case-control study was conducted on 21 patients with AML and 9 healthy individuals. The expressions of miR-155, KRAS, and CREB were measured using RT-PCR. Demographic data were extracted from the documents of individuals. SPSS and GraphPad Prism software were used to analyze the data.
Results:
The expression of miR-155 in patients with AML was 35 times higher than in the control group (p < 0.0001). Also, CREB fold change increased by 1.92-fold in patients compared to the controls (p = 0.034), but no difference in KRAS was observed between the control and AML groups (p > 0.05). There was no change in miR-155, CREB, and KRAS expression based on gender, age, and blast percentage (p > 0.5). Nevertheless, there was a direct correlation between CREB and KRAS expressions (p = 0.0002). Our result showed that overexpression of CREB and KRAS would cause an increase in white blood cells (WBCs) (p = 0.001, 0.045 respectively), but there was no correlation between miR-155 with WBCs (p > 0.5).
Conclusions:
Our study revealed that miR-155 and CREB had overexpression compared to the control group.
Insights
MicroRNA-155 (miR-155) and CREB are overexpressed in acute myeloid leukemia (AML). While miR-155 and CREB show increased expression in AML patients, KRAS does not, though CREB and KRAS correlate.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer characterized by genetic and microRNA (miRNA) aberrations.
- MicroRNAs are key regulators in cancer development and progression.
- This study investigates the interplay between miR-155, KRAS, and CREB in AML.
Purpose of the Study:
- To determine the expression levels of miR-155, KRAS, and CREB in AML patients compared to healthy controls.
- To explore the correlation between these molecules and their potential impact on clinical parameters.
- To elucidate the relationship between miR-155, KRAS, and CREB in the context of AML pathogenesis.
Main Methods:
- A case-control study involving 21 AML patients and 9 healthy controls.
- Quantitative real-time PCR (RT-PCR) was utilized to measure the expression of miR-155, KRAS, and CREB.
- Statistical analysis was performed using SPSS and GraphPad Prism software.
Main Results:
- miR-155 expression was significantly higher (35-fold) in AML patients versus controls (p < 0.0001).
- CREB expression showed a 1.92-fold increase in AML patients (p = 0.034), while KRAS expression remained unchanged (p > 0.05).
- A direct correlation was observed between CREB and KRAS expression (p = 0.0002), and both were linked to increased white blood cell counts.
Conclusions:
- miR-155 and CREB are significantly overexpressed in acute myeloid leukemia.
- The findings highlight potential roles for miR-155 and CREB in AML development.
- Further research is warranted to explore the therapeutic implications of targeting these molecules in AML.
Related Concept Videos
Abnormal Proliferation
Master Transcription Regulators
The Ras Gene
Ras is a...

